The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21.1 - Manufacture of basic pharmaceutical products
300 jobs Number of planned job losses
Announcement Date
25 January 2018
Employment effect (start)
25 January 2018
Foreseen end date
31 December 2018
Description
The German pharmaceutical company Ratiopharm, owned by the Israeli pharmaceutical company Teva, announced it will cut 300 jobs in Germany due to internal restructuring. The job losses will fall in Ratiopharm's sites in Ulm and Blaubeuren and the site in Berlin which will be shut down. The job reduction follows an announcement by Teva dating back to December 2017, announcing the loss of 14,000 jobs worldwide.
Negotiations between management and employee representatives will start shorty.
26 January 2018: Deutsche Apotheker Zeitung (online)
Citation
Eurofound (2018), Ratiopharm, Internal restructuring in Germany, factsheet number 93162, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/93162.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
